Clinical trials: Attention Deficit and Hyperactivity Disorder (ADHD)
- Condition Attention Deficit and Hyperactivity Disorder (ADHD)
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years).
- Trial name
- NCT02466425
- Testing
- SHP465
- Where
- 36 sites in United States
- Volunteers
- 264 people
- Sponsor
- Shire
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder
Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children
Principal focus is to evaluate the effects of omega 3 fatty acids supplementation on the ADHD children's behaviour during 12 weeks on two years.
- Trial name
- NCT00770627
- Testing
- Omega 3 caps
- Where
- 2 sites in France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Laboratoires URGO
ADHD
Evaluation of Use of Brain Activity Monitoring Dynamics in ADHD
This study evaluates the ability to support diagnosis and monitor of the dynamics in ADD/ADHD subjects with an easy to use EEG Device.
- Trial name
- NCT02625805
- Testing
- EEG monitoring (MindWave by NeuroSky), EEG monitoring (EPOC by Emotiv), Methylphenidate
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brainmarc Ltd.
Attention-Deficit Hyperactivity Disorder(ADHD)
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
- Trial name
- NCT07086313
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
ADHD
Assessing a Wearable Digital Therapy for Youth With ADHD
The purpose of this study is to evaluate and compare three different investigational wearable digital interventions to determine if they are helpful for improving symptoms and functioning in children diagnosed with…
- Trial name
- NCT05710965
- Testing
- FRx-001, FRx-003, FRx-004
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Revibe Technologies
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at 6.25 milligram (mg) in children aged 4 to 12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03325894
- Testing
- SHP465
- Where
- 48 sites in United States
- Volunteers
- 141 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
- Trial name
- NCT03247530
- Testing
- 100mg SPN-812, 200mg SPN-812
- Where
- 7 sites in United States
- Volunteers
- 477 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the effectiveness and safety of methylphenidate HCl extended-release tablets at five dose levels compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT00326391
- Testing
- methylphenidate hydrochloride extended-release tablets
- Volunteers
- 229 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00568685
- Testing
- Atomoxetine Hydrochloride
- Where
- 3 sites in South Korea
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
This study is a multi-center, randomized, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
- Trial name
- NCT02477748
- Testing
- MDX
- Where
- 38 sites in United States, Israel
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Alcobra Ltd.
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea
ADHD
Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD
Evaluate the behavioral effects of ADDERALL XR versus STRATTERA under controlled conditions utilizing the SKAMP deportment scale.
- Trial name
- NCT00506727
- Testing
- Mixed amphetamine salts (ADDERALL XR), Atomoxetine hydrochloride
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
- Trial name
- NCT04113551
- Testing
- MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO)
- Where
- United States
- Volunteers
- 17,418 people
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit/Hyperactivity Disorder (ADHD)
The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder
The primary objective of this trial is to determine whether an oral administration of Phosphatidylserine-Omega3 would significantly improve the clinical symptoms of children suffering from ADHD.
- Trial name
- NCT00418184
- Testing
- Phosphatidylserine-Omega3, Colored cellulose tainted with fishy odor
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Enzymotec
ADHD
CTx-1301 Comparative Bioavailability Study
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301.
- Trial name
- NCT04138498
- Testing
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
Open-label trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 years with Attention- Deficit/Hyperactivity Disorder
- Trial name
- NCT00191880
- Testing
- atomoxetine
- Where
- 8 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
- Trial name
- NCT00152009
- Testing
- SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg)
- Volunteers
- 345 people
- Sponsor
- Shire